Capital Fund Management Boosts Stake in Halozyme Therapeutics

Institutional investor increases holding in biopharmaceutical company by 97%

Mar. 12, 2026 at 8:24am

Got story updates? Submit your updates here. ›

Capital Fund Management S.A. grew its stake in shares of Halozyme Therapeutics, Inc. (NASDAQ:HALO) by 97.1% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund now owns 212,741 shares of the biopharmaceutical company's stock, worth $15.6 million.

Why it matters

Halozyme Therapeutics is a San Diego-based biopharmaceutical company that specializes in drug delivery technologies. The significant increase in Capital Fund Management's stake suggests the institutional investor sees strong potential in the company's proprietary ENHANZE platform and pipeline of novel therapies.

The details

Capital Fund Management acquired an additional 104,830 shares of Halozyme Therapeutics in the third quarter, bringing its total holding to 212,741 shares. The investment firm now owns approximately 2.7% of the company's outstanding stock. Halozyme Therapeutics is focused on enabling subcutaneous administration of biologic therapies through its ENHANZE technology, which uses a recombinant human hyaluronidase enzyme to temporarily degrade hyaluronan in the extracellular matrix.

  • Capital Fund Management increased its Halozyme Therapeutics stake in the 3rd quarter of 2026.

The players

Capital Fund Management S.A.

A global investment management firm that oversees over $30 billion in assets.

Halozyme Therapeutics, Inc.

A San Diego-based biopharmaceutical company that specializes in drug delivery technologies, including its proprietary ENHANZE platform.

Got photos? Submit your photos here. ›

The takeaway

Capital Fund Management's increased stake in Halozyme Therapeutics suggests the institutional investor sees strong growth potential in the company's innovative drug delivery technologies and pipeline. This could signal positive momentum for Halozyme as it continues to advance its ENHANZE platform and novel therapies.